SSA
SKYE icon

Schonfeld Strategic Advisors’s Skye Bioscience SKYE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,676
Closed -$70K – 2764
2025
Q4 		$70K Sell
11,676
-136,726
-92% -$1.6M ﹤0.01% 1857
2025
Q3 		$4.67M Buy
148,402
+11,169
+8% +$337K 0.03% 609
2025
Q2 		$4.59M Sell
137,233
-64,908
-32% -$1.07M 0.03% 595
2025
Q1 		$2.57M Buy
202,141
+24,298
+14% +$531K 0.02% 838
2024
Q4 		$4.03M Buy
177,843
+57,956
+48% +$1.94M 0.02% 572
2024
Q3 		$3.75M Buy
119,887
+65,968
+122% +$2.96M 0.03% 637
2024
Q2 		$3.46M Buy
+53,919
New +$5.12M 0.02% 680

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Schonfeld Strategic Advisors's SKYE Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Skye Bioscience (SKYE) in Q1 2026, closing a stake of 11,676 shares — an estimated $70K sold.

Schonfeld Strategic Advisors first reported a position in SKYE in Q2 2024 and held it in 7 quarters. The position peaked at $4.67M in Q3 2025. 31 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Skye Bioscience position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 11,676 Skye Bioscience shares in Q1 2026, an estimated $70K.
  • Schonfeld Strategic Advisors first reported a position in Skye Bioscience in Q2 2024 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's Skye Bioscience position peaked at $4.67M in Q3 2025.
  • 31 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.